K. Kaiser
Rush University Medical Center
8 Papers
66 Citations
K. Kaiser is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Gefitinib. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Mary J. Fidler,Athanassios Argiris,Jyoti D. Patel,David H. Johnson,Alan B. Sandler,Victoria M. Villaflor,John S. Coon,Lela Buckingham,K. Kaiser,Sanjib Basu,Philip Bonomi +10 more
TL;DR: GIB observed in this trial supports excluding patients with a history of peptic ulcer disease or those requiring therapeutic anticoagulation from future EGFR and COX-2 inhibitor studies, as well as longer PFS with high-tumor COx-2 expression suggests that trials of EG FR and CO X-2 inhibitors may be warranted in this patient subset.
64
The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib
Lela Buckingham,John S. Coon,Larry E. Morrison,Kristine Jacobson,Susan Jewell,K. Kaiser,Ann M. Mauer,T. Muzzafar,Clayton Polowy,Sanjib Basu,Meryl Gale,Victoria M. Villaflor,Philip Bonomi +12 more
TL;DR: It is suggested that further study of chromosome 7 polysomy and of pAKT and PTEN expression in patients treated with EGFR tyrosine kinase inhibitors is warranted in developing a clinical test for selecting patients for gefitinib therapy.
42
Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib
TL;DR: The objective was to associate clinical outcomes of advanced NSCLC gefitinib treated patients (pts) with IGFR-1 expression, which has been hypothesized to impart resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
15
EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts)
Victoria M. Villaflor,Lela Buckingham,Meryl Gale,John S. Coon,Ann M. Mauer,T. Muzzafar,K. Kaiser,T. W. Zusag,L. P. Faber,P. Bonomi +9 more
TL;DR: In this article, mutations in exons 18 and 21 of the EGFR gene have been found in tumors from NSCLC pts that respond to gefitinib (GEF).
12
EGFR mutations (muts), IHC and FISH status, and chromosome 7 gene copy number combined with pAkt expression as potential predictors of survival in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib (GEF)
Victoria M. Villaflor,Lela Buckingham,Meryl Gale,John S. Coon,Ann M. Mauer,T. Muzzafar,K. Kaiser,M. Shannon,Larry E. Morrison,P. Bonomi +9 more
TL;DR: These findings resemble but do not duplicate those reported by Cappuzzo, et al.
9